Can lansoprazole, amoxicillin, and clarithromycin combination still be used as a first-line therapy for eradication of helicobacter pylori?

Turkish Journal of Gastroenterology

Volumn 16, Issue 1, 2005, Pages 29-33

  Güliter, Sefa ^a,b   Keleş, Hatice ^a   Özkurt, Zübeyde Nur ^a   Cengiz, Derya U ^a   Kolukisa, Emre ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b Aydinlikevler Mahallesi   (Turkey)

Author keywords

Amoxicillin; Clarithromycin; Helicobacter pylori eradication; Lansoprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; UREASE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; DIAGNOSTIC TEST; DIARRHEA; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPIC BIOPSY; EPIGASTRIC PAIN; ERADICATION THERAPY; FATIGUE; FEMALE; GASTRITIS; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; SMOKING; STATISTICAL ANALYSIS; STOMACH ULCER; TASTE DISORDER; TURKEY (REPUBLIC); ULCER HEALING;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ACUTE DISEASE; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; BIOPSY; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; DUODENAL ULCER; DYSPEPSIA; ENDOSCOPY, GASTROINTESTINAL; FEMALE; FOLLOW-UP STUDIES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL MUCOSA; MALE; OMEPRAZOLE; PROTON PUMPS; RETROSPECTIVE STUDIES; STOMACH ULCER; TREATMENT OUTCOME;

EID: 17644416776     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Graham DY, Evans DG, Evans DJ Jr. Campylobacter pylori. The organism and its clinical relevance. J Clin Gastroenterol 1989; 11 (Suppl 1): S43-8.
2. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991; 338; 1175-6.
3. Coghlan JG, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers: a 12-month follow-up study. Lancet 1987 Nov 14; 2(8568): 1109-11.
4. Malfertheiner P, Megraud F, O'Morain C, et al. and the European Helicobacter Pylori Study Group (EPHSG). Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
5. Hunt RH. Eradication of H. pylori infection. Am J Med 1996; 100: 42-51.
6. Daw MA, Deegan P, Leen E, O'Morain C. Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis. Aliment Pharmacol Ther 1991; 5: 435-9.
7. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pomp inhibitor, and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6.
8. Graham DY. Clarithromycin for treatment of H. pylori infection. Eur J Gastroenterol Hepatol 1995; 7 (Suppl 1): 55-8.
9. Leung WK, Graham DY. Clarithromycin for Helicobacter pylori infection. Expert Opin Pharmacother 2000; 1: 507-14.
10. Wolle K, Leodolter A, Malfertheiner P, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51; 705-9.
11. Boyanova L, Mentis A, Gubina M, et al. The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 2002; 8: 388-96.
12. Sezgin O, Altintaş E, Ulu O, et al. H. pylori eradikasyonunda üç farkli proton pompasi inhibitörünün karşilaştirilmasi (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/23.
13. Telaku S, Hatemi I, Erdamar S, et al. Helicobacter pylori eradikasyonunda 1 ve 2 haftalik lansoprazole-amoxicilline-clarithromycin protokollerinin karşilaştirilmasi (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/46.
14. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 16: 1311-5.
15. Graham DY, Opekun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J Clin Gastroenterol 1993; 16: 292-4.
16. Al-Assi MT, Genta RM, Karttunen TJ, et al. Clarithromycin-amoxicillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 453-6.
17. The European Helicobacter Pylori Group. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8-13.
18. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods of twice a day triple therapy for the eradication on Helicobacter pylori. Aliment Pharmacol Ther 1996; 10: 1029-33.
19. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35: 323-6.
20. Moayyedi P, Langworthy H, Shanahan K, et al. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter 1996; 1: 71-4.
21. Aydin A, Özütemiz Ö, Ersöz G, et al. Helicobacter pylori eradikasyonunda omeprazol veya lansoprazol ile yapilan bir haftalik üçlü tedavilerin karşilaştirilmasi (Abstract). Turk J Gastroenterol 1997; 8 (Suppl 1): P 198.
22. Aladaǧ M, Karincaoǧlu M, Kantarçeken B, et al. Helicobacter pylori eradikasyonunda proton pompa inhibitörlerinin etkinliklerinin (lansoprazol ve omeprazol) kiyaslanmasi. Turgut Özal Tip Merkezi Dergisi 1999; 6: 92-9.
23. Kaya N, Eser Ş, Coşar A, et al. Nonülser dispepsi olgularinda Helicobacter pylori eradikasyonunun semptomlara etkisi (Abstract). Turk J Gastroenterol 1997; 8 (Suppl 1): P 192.
24. Rinaldi V, Zullo A, De Francesco V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther 1999; 13: 163-8.
25. Lamouliatte H, Cayla R, Megraud F. Treatment of Helicobacter pylori infection. Rev Prat 2000; 50: 1442-5.
26. Şimşek İ, Soytürk M, Akpinar H, et al. Bir ve iki haftalik üçlu eradikasyon tedavilerinden sonra Helicobacter pylori reinfeksiyon oranlari: 17 aylik izlem sonuçlari (Abstract). Turk J Gastroenterol 2000; 11 (Suppl 1): P 154.
27. Özaslan E, Balaban Y, Tatar G, et al. Helicobacter pylori eradikasyonunda en yaygin kullanilan rejimin (lansoprazol+amoksisilin+klaritromisin) başarisi azaliyor mu (Abstract)? Turk J Gastroenterol 2001; 12 (Suppl 1): P-B/50.
28. Erçin N, Yeşilova Z, Gülşen M, et al. Helicobacter pylori pozitif non-ülser dispepsili hastalarda eradikasyon tedavisinde kullanilan deǧişik protokollerin karş ilaştirilmasi (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/11.
29. Sezgin O, Altintaş E, Ulu O, et al. Helikobakter pylori eradikasyonunda üç farkli proton pompasi inhibitörünü n karşilaştirilmasi (Abstract). Turk J Gastroenterol 2002; 13 (Suppl 1): PB4/23.
30. Alkim H, İşcan M. Helikobakter pylori eradikasyonunda ranitidin bizmut sitratli ve proton pompa inhibitörlü kombinasyonlarin etkinliǧinin karşilaştirilmasi (Abstract). Turk J Gastroenterol 2003; 14 (Suppl 1): PB.08/36.
31. Gümürdülü Y, Serin E, Özer B, et al. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey. World J Gastroenterol 2004; 10: 668-71.
32. Vakil N, Hahn B, McSorley D. Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-5.
33. Crone J, Granditsch G, Huber WD, et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003; 36: 311-3.
34. Tankovic J, Lamarque D, Lascols C, et al. Impact of Helicobacter pylori resistance to clarithromycin on the efficacy of the omeprazole-amoxicillin- clarithromycin therapy. Aliment Pharmacol Ther 2001; 15: 707-13.
35. Cabrita J, Oleastro M, Matos R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46: 1029-31.
36. Wolle K, Leodolter A, Malfertheiner P, et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-9.
37. Hulten K, Gibreel A, Skold O, et al. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 1997; 41: 2550-3.
38. Chiba N. Effects of in vitro antibiotic resistance on treatment: bismuth-containing regimens. Can J Gastroenterol 2000; 14: 885-9.
39. Palabiyikoǧlu M, Şahin F, Özden A, et al. Disk diffüzyon yöntemi ile Helicobacter pylori klinik izolatlarinda amoksisiline ve klaritromisine karşi primer duyarliliǧin araştirilmasi ve tedavi sonrasi muhtemel duyarlilik deǧiş ikliǧinin incelenmesi. Turk J Gastroenterol 1997; 8: 309-12.
40. Kantarçeken B, Yildirim B, Karincaoǧlu M, et al. Helicobacter pylori and antibiotic resistance. Turk J Gastroenterol 2000; 11; 141-5.
41. Engin D, Erciş S, Özaslan E, et al. E-test yöntemi ile Helicobacter pylorinin çeşitli antibiyotiklere karşi duyarliliǧinin belirlenmesi (Abstract). Turk J Gastroenterol 2001; 12 (Suppl 1): S-B/15.
42. Çirak MY, Ünal S, Türet S, et al. Helicobacter pyloride klaritromisin direncinin genetik olarak belirlenmesi (Abstract). Turk J Gastro 2003; 14 (Suppl 1): SB.00/5.
43. Işiksal F, Çolakoǧlu S, Köksal F, et al. Helicobacter pylori-antibiyotik direnci (Abstract). Turk J Gastro 2003; 14 (Suppl 1): SB.07/5.